Publikationen, an denen er mitarbeitet Miquel Bernardo Arroyo (60)

2025

  1. Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case–Control Analysis from the First Episode Case–Control EU-GEI WP2 Study: L’arrêt de l’utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de l’étude cas-témoins EU-GEI WP2 centrée sur les premiers épisodes psychotiques

    Canadian Journal of Psychiatry, Vol. 70, Núm. 3, pp. 182-193

  2. Cognitive presentation at psychosis onset through premorbid deterioration and exposure to environmental risk factors

    Psychological Medicine, Vol. 55

  3. Methylomic signature of current cannabis use in two first-episode psychosis cohorts

    Molecular Psychiatry, Vol. 30, Núm. 4, pp. 1277-1286

  4. Variation of subclinical psychosis as a function of population density across different European settings: Findings from the multi-national EU-GEI study

    Acta Psychiatrica Scandinavica, Vol. 151, Núm. 4, pp. 506-520

2024

  1. Basic quality indicators for clinical care of patients with major depression, schizophrenia, and bipolar disorder

    Spanish Journal of Psychiatry and Mental Health, Vol. 17, Núm. 2, pp. 103-109

  2. Cannabis use and cognitive biases in people with first-episode psychosis and their siblings

    Psychological Medicine

  3. Clustering Schizophrenia Genes by Their Temporal Expression Patterns Aids Functional Interpretation

    Schizophrenia Bulletin, Vol. 50, Núm. 2, pp. 327-338

  4. Self-reported suicidal ideation among individuals with first episode psychosis and healthy controls: Findings from the international multicentre EU-GEI study

    Schizophrenia Research, Vol. 270, pp. 339-348

  5. The Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study

    Schizophrenia Bulletin, Vol. 50, Núm. 5, pp. 1039-1049

  6. The effect of polygenic risk score and childhood adversity on transdiagnostic symptom dimensions at first-episode psychosis: evidence for an affective pathway to psychosis

    Translational Psychiatry, Vol. 14, Núm. 1

  7. The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies

    Psychological Medicine

  8. Variation of subclinical psychosis across 16 sites in Europe and Brazil: findings from the multi-national EU-GEI study

    Psychological medicine, Vol. 54, Núm. 8, pp. 1810-1823

2023

  1. Basic quality indicators for clinical care of patients with major depression, schizophrenia, and bipolar disorder

    Revista de Psiquiatria y Salud Mental

  2. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  3. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)

    The Lancet Psychiatry, Vol. 10, Núm. 3, pp. 197-208

  4. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    Psychiatry Research, Vol. 323

  5. Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis—findings from the EU-GEI study

    Molecular Psychiatry, Vol. 28, Núm. 5, pp. 2095-2106

2022

  1. A replication study of JTC bias, genetic liability for psychosis and delusional ideation

    Psychological Medicine, Vol. 52, Núm. 9, pp. 1777-1783

  2. Childhood Maltreatment, Educational Attainment, and IQ: Findings from a Multicentric Case-control Study of First-episode Psychosis (EU-GEI)

    Schizophrenia Bulletin, Vol. 48, Núm. 3, pp. 575-589

  3. Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

    Schizophrenia, Vol. 8, Núm. 1